Molecular mechanisms of amyloid oligomers toxicity

Advances in Alzheimer's Disease

Volumn 3, Issue , 2012, Pages 67-78

  Kayed, Rakez ^a   Lasagna Reeves, Cristian A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer's disease; amyloid; amyloid oligomers; amyloid toxicity

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CALCINEURIN; COFILIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; PRION PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CELLULAR DISTRIBUTION; HUMAN; MOLECULAR PATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

EID: 84877986609     PISSN: 22105727     EISSN: 22105735     Source Type: Book Series    
DOI: 10.3233/978-1-61499-154-0-67     Document Type: Article

References (143)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
2. Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 41, 1261-1268.
3. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
4. Cappai R, Barnham KJ (2008) Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem Res 33, 526-532.
5. Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M (2006) Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 26, 8160-8167.
6. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
7. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866.
8. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T,Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862.
9. Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35, 352-358.
10. Gaspar RC, Villarreal SA, Bowles N, Hepler RW, Joyce JG, Shughrue PJ (2010) Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. Exp Neurol 223, 394-400.
11. Takahashi RH, Almeida CG,Kearney PF,Yu F, LinMT,Milner TA, Gouras GK (2004) Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24, 3592-3599.
12. Ross CA, Poirier MA (2005) Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 6, 891-898.
13. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267-298.
14. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27, 570-575.
15. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283, 29639-29643.
16. Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, S74-S78.
17. Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja L, Jayasinghe S, Langen R, Glabe CG, Butler PC (2006) Inhibition of human IAPP fibril formation does not prevent beta-cell death: Evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab 291, E1317-E1324.
18. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
19. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284, 4230-4237.
20. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18.
21. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
22. Kayed R, Glabe CG (2006) Conformation-dependent antiamyloid oligomer antibodies. Methods Enzymol 413, 326-344.
23. Necula M, Kayed R, Milton S, Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282, 10311-10324.
24. Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ (2006) ERK1/2 activation mediates Abeta oligomerinduced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 281, 20315-20325.
25. Cizas P, Budvytyte R, Morkuniene R, Moldovan R, Broccio M, Losche M, Niaura G, Valincius G, Borutaite V (2010) Size-dependent neurotoxicity of beta-amyloid oligomers. Arch Biochem Biophys 496, 84-92.
26. Zako T (2010) Amyloid oligomers. FEBS J 277, 1347.
27. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, NairnAC, SalterMW, Lombroso PJ, Gouras GK, Greengard P (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8, 1051-1058.
28. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, Yanagisawa K (2007) A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem 282, 2646-2655.
29. Hansma HG, Laney DE, Bezanilla M, Sinsheimer RL, Hansma PK (1995) Applications for atomic force microscopy of DNA. Biophys J 68, 1672-1677.
30. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (Mosc) 42, 12749-12760.
31. Rabizadeh S, Bitler CM, Butcher LL, Bredesen De (1994) Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity. Proc Natl Acad Sci U S A 91, 10703-10706.
32. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA (1997) Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J Clin Invest 100, 2333-2340.
33. Yaar M, Zhai S, Fine RE, Eisenhauer PB, Arble BL, Stewart KB, Gilchrest BA (2002) Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J Biol Chem 277, 7720-7725.
34. Kuner P, Schubenel R, Hertel C (1998) Beta-amyloid binds to p57NTR and activates NFkappaB in human neuroblastoma cells. J Neurosci Res 54, 798-804.
35. Perini G, Della-Bianca V, Politi V, Della Valle G, Dal-Pra I, Rossi F, ArmatoU(2002) Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med 195, 907-918.
36. Tsukamoto E, HashimotoY, Kanekura K, Niikura T, Aiso S, Nishimoto I (2003) Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. J Neurosci Res 73, 627-636.
37. Costantini C, Rossi F, Formaggio E, Bernardoni R, Cecconi D, Della-Bianca V (2005) Characterization of the signaling pathway downstream p75 neurotrophin receptor involved in beta-amyloid peptide-dependent cell death. J Mol Neurosci 25, 141-156.
38. Bothwell M (1996) p75NTR: A receptor after all. Science 272, 506-507.
39. Dechant G, Barde YA (2002) The neurotrophin receptor p75(NTR): Novel functions and implications for diseases of the nervous system. Nat Neurosci 5, 1131-1136.
40. Zhang Y, Hong Y, Bounhar Y, Blacker M, Roucou X, Tounekti O, Vereker E, Bowers WJ, Federoff HJ, Goodyer CG, LeBlanc A (2003) p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 23, 7385-7394.
41. Yamin G (2009)NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res 87, 1729-1736.
42. Zhao D,Watson JB, Xie CW (2004) Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol 92, 2853-2858.
43. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-Daspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590-11601.
44. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptordependent signaling pathway. J Neurosci 27, 2866-2875.
45. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260.
46. Townsend M, Mehta T, Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282, 33305-33312.
47. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer'slinked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106, 1971-1976.
48. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST (2008) Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283, 9359-9368.
49. Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ (2001) Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Nature 412, 86-90.
50. Gordon MD, Nusse R (2006) Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281, 22429-22433.
51. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132.
52. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, RydelRE(1992) beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12, 376-389.
53. Mattson MP (1994) Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Ann N Y Acad Sci 747, 50-76.
54. Arispe N, Pollard HB, Rojas E (1993) Giant multilevel cation channels formed by Alzheimer disease amyloid betaprotein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci U S A 90, 10573-10577.
55. Arispe N, Rojas E, Pollard HB (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A 90, 567-571.
56. Kawahara M, Kuroda Y, Arispe N, Rojas E (2000) Alzheimer's beta -Amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 275, 14077-14083.
57. Kagan BL, Azimov R, Azimova R (2004) Amyloid peptide channels. J Membr Biol 202, 1-10.
58. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC (2002) The channel hypothesis of Alzheimer's disease: Current status. Peptides 23, 1311-1315.
59. Bechinger B (1997) Structure and functions of channelforming peptides: Magainins, cecropins, melittin and alamethicin. J Membr Biol 156, 197-211.
60. Yatin SM, Aksenova M, Aksenov M, Markesbery WR, Aulick T, Butterfield DA (1998) Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses. J Mol Neurosci 11, 183-197.
61. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K (1993) Tau protein kinase I is essential for amyloid betaprotein-induced neurotoxicity. Proc Natl Acad Sci U S A 90, 7789-7793.
62. Lasagna-Reeves CA, Glabe CG, Kayed R (2011) Amyloidbeta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem 286, 22122-22130.
63. Lasagna-Reeves CA, Kayed R (2011) Astrocytes contain amyloid-beta annular protofibrils in Alzheimer's disease brains. FEBS Lett 585, 3052-3057.
64. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279, 46363-46366.
65. Klein WL, Stine WB Jr, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25, 569-580.
66. Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81, 678-699.
67. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11, 213-228.
68. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG(2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280, 17294-17300.
69. Porat Y, Kolusheva S, Jelinek R, Gazit E (2003) The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42, 10971-10977.
70. Canale C, Torrassa S, Rispoli P, Relini A, Rolandi R, Bucciantini M, Stefani M, Gliozzi A (2006) Natively folded HypF-N and its early amyloid aggregates interact with phospholipid monolayers and destabilize supported phospholipid bilayers. Biophys J 91, 4575-4588.
71. Butterfield SM, LashuelHA(2010) Amyloidogenic proteinmembrane interactions: Mechanistic insight from model systems. Angew Chem Int Ed Engl 49, 5628-5654.
72. Lashuel HA, Lansbury PT Jr (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial poreforming toxins? Q Rev Biophys 39, 167-201.
73. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
74. Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, Sokolov Y, Hall JE, Losche M (2008) Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: Implications for cell toxicity. Biophys J 95, 4845-4861.
75. Green JD, Kreplak L, Goldsbury C, Li Blatter X, Stolz M, Cooper GS, Seelig A, Kistler J, Aebi U (2004) Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J Mol Biol 342, 877-887.
76. Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE (2006) Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128, 637-647.
77. Hannig J, Zhang D, Canaday DJ, Beckett MA, Astumian RD, Weichselbaum RR, Lee RC (2000) Surfactant sealing of membranes permeabilized by ionizing radiation. Radiat Res 154, 171-177.
78. Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M (2004) Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 279, 31374-31382.
79. Mattson MP, Barger SW, Cheng B, Lieberburg I, Smith-Swintosky VL, Rydel RE (1993) beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci 16, 409-414.
80. Neumcke B, Lauger P (1969) Nonlinear electrical effects in lipid bilayer membranes. II. Integration of the generalized Nernst-Planck equations. Biophys J 9, 1160-1170.
81. ParsegianA(1969) Energy of an ion crossing a lowdielectric membrane: Solutions to four relevant electrostatic problems. Nature 221, 844-846.
82. Demuro A, Smith M, Parker I (2011) Single-channel Ca(2+) imaging implicates Abeta1-42 amyloid pores in Alzheimer's disease pathology. J Cell Biol 195, 515-524.
83. Ellis G, Fang E, Maheshwari M, Roltsch E, Holcomb L, Zimmer D, Martinez D, Murray IV (2010) Lipid oxidation and modification of amyloid-beta (Abeta) in vitro and in vivo. J Alzheimers Dis 22, 593-607.
84. Murray IV, Sindoni ME, Axelsen PH (2005) Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry 44, 12606-12613.
85. Glabe C (2001) Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci 17, 137-145.
86. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
87. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010) Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 119, 523-541.
88. D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120-134.
89. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, RelkinNR(2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15-20.
90. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC (2001) Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125, 489-492.
91. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, JayG (1997) Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 100, 310-320.
92. Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, Duyckaerts C (2004) Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol 165, 1465-1477.
93. Skovronsky DM, Doms RW, Lee VM (1998) Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol 141, 1031-1039.
94. Wirths O, Multhaup G, Czech C, BlanchardV, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA (2001) Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 doubletransgenic mice. Neurosci Lett 306, 116-120.
95. Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK (2005) Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 20, 187-198.
96. Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van Der Kolk N, Vingtdeux V, van De Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165, 1289-1300.
97. Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML (2004) Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol 33, 377-387.
98. Mori C, Spooner ET,Wisniewsk KE,Wisniewski TM,Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA (2002) Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9, 88-102.
99. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058.
100. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
101. Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25, 7278-7287.
102. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161, 1869-1879.
103. Yang AJ, Chandswangbhuvana D, Shu T, Henschen A, Glabe CG (1999) Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor proteintransfected cells that have been treated with Abeta1-42. J Biol Chem 274, 20650-20656.
104. Bahr BA, Hoffman KB, Yang AJ, Hess US, Glabe CG, Lynch G (1998) Amyloid beta protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol 397, 139-147.
105. Burdick D, Kosmoski J, Knauer MF, Glabe CG (1997) Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A beta 1-42, in differentiated PC12 cells. Brain Res 746, 275-284.
106. Yang AJ, Knauer M, Burdick DA, Glabe C (1995) Intracellular A beta 1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem 270, 14786-14792.
107. Xu H, Greengard P, Gandy S (1995) Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. J Biol Chem 270, 23243-23245.
108. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT (2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 116, 3339-3346.
109. Mizuguchi M, Ikeda K, Kim SU (1992) Differential distribution of cellular forms of beta-amyloid precursor protein in murine glial cell cultures. Brain Res 584, 219-225.
110. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D'Andrea MR, Dinsmore S, Nagele RG (2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223-236.
111. Yu C, Nwabuisi-Heath E, Laxton K, Ladu MJ (2010) Endocytic pathways mediating oligomeric Abeta42 neurotoxicity. Mol Neurodegener 5, 19.
112. Nagele RG, D'Andrea MR, Anderson WJ,WangHY(2002) Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110, 199-211.
113. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000) beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275, 5626-5632.
114. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, Leslie FM, LaFerla FM (2005) Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A 102, 3046-3051.
115. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT (2010) Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating earlystage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 30, 2442-2453.
116. Bu G, Cam J, Zerbinatti C (2006) LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci 1086, 35-53.
117. Deane R, DuYan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C,Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913.
118. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
119. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 888, 256-262.
120. Du Yan S, Zhu H, Fu J, Yan SF, Roher A, TourtellotteWW, Rajavashisth T, Chen X, Godman GC, Stern D, SchmidtAM (1997) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 94, 5296-5301.
121. Almeida CG, Takahashi RH, Gouras GK (2006) Betaamyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 26, 4277-4288.
122. Oh S, Hong HS, Hwang E, Sim HJ, LeeW, Shin SJ, Mook-Jung I (2005) Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech Ageing Dev 126, 1292-1299.
123. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM (2008) Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 29, 1607-1618.
124. Rosario ER, Carroll JC, Oddo S, LaFerla FM, PikeCJ (2006) Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci 26, 13384-13389.
125. Mousnier A, Kubat N, Massias-Simon A, Segeral E, Rain JC, Benarous R, Emiliani S, DargemontC(2007) von Hippel Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step. Proc Natl Acad Sci U S A 104, 13615-13620.
126. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
127. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19, 2040-2041.
128. Keil U, Hauptmann S, Bonert A, Scherping I, Eckert A, Muller WE (2006) Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein mutations. J Alzheimers Dis 9, 139-146.
129. Chyung JH, Raper DM, Selkoe DJ (2005) Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J Biol Chem 280, 4383-4392.
130. Nixon RA,Wegiel J,Kumar A,YuWH,PeterhoffC, Cataldo A, Cuervo AM (2005) Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J Neuropathol Exp Neurol 64, 113-122.
131. Nixon RA, Cataldo AM (2006) Lysosomal system pathways: Genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis 9, 277-289.
132. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52, 691-698.
133. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 25, 1071-1080.
134. Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA (2011) Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem 286, 8585-8596.
135. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R 3rd, Pensalfini A, Yeung S, Head E, Marsh JL, Glabe C (2010) Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol Neurodegener 5, 57.
136. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R (2005) Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307, 262-265.
137. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R (2005) 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A 102, 17342-17347.
138. Kodali R, Williams AD, Chemuru S, Wetzel R (2010) Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities correlate. J Mol Biol 401, 503-517.
139. Miller Y, Ma B, Nussinov R (2010) Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev 110, 4820-4838.
140. Wu JW, Breydo L, Isas JM, Lee J,Kuznetsov YG, Langen R, Glabe C (2010) Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem 285, 6071-6079.
141. Deshpande A, Mina E, Glabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26, 6011-6018.
142. Tanaka M, Collins SR, Toyama BH, Weissman JS (2006) The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585-589.
143. Toyama BH, Kelly MJ, Gross JD,Weissman JS (2007) The structural basis of yeast prion strain variants. Nature 449, 233-237.